CVS Beats by a Penny, Guidance Narrowed - Analyst Blog
August 04 2011 - 7:35AM
Zacks
CVS Caremark (CVS) reported second quarter 2011
EPS of 60 cents, at par with the year-ago quarter earnings.
However, after excluding the impact of certain one-time items,
adjusted earnings per share came in at 65 cents, surpassing the
Zacks Consensus Estimate by a penny but meeting the year-ago
quarter’s adjusted earnings.
Net revenues increased 10.9% year over year to $26.6 billion, in
line with the Zacks Consensus Estimate.
The Pharmacy Services segment recorded a robust 23.2% increase
in revenues in the quarter to $14.6 billion. The significant growth
was primarily driven by the long-term contract with
Aetna (AET) as well as the new acquisition of the
Medicare Part D business of Universal American
Corp. (UAM).
These contracts, combined with an increase in covered lives in
the company’s existing Medicare Part D business, also led to a
35.6% year-over-year rise in CVS’ pharmacy network claims to 174.0
million. The Aetna contract also drove the Mail Choice claims
processed growth by 11.3% to 17.8 million.
Revenues from CVS’ Retail Pharmacy increased 3.6% to $14.8
billion during the quarter with same-store sales climbing 2.0%.
While pharmacy same-store sales rose 2.6%, front-end same-store
sales inched up 0.8%.
Pharmacy same-store sales witnessed a 170-basis point drop due
to recent generic introductions, whereas the Maintenance Choice
program had a positive impact of 160 basis points on a net basis.
The front-store sales grew 45 basis points due to the shift of
Easter holiday related sales into the second quarter.
In April 2011, CVS acquired Universal American’s Medicare Part D
business. Subsequent to this acquisition, CVS provides Medicare
Part D benefits to over 3 million beneficiaries.
During the first quarter, CVS opened 41 new retail drugstores,
closed 2 retail specialty pharmacy stores, 5 specialty mail order
pharmacies, 1 retail apothecary pharmacy store and 1 retail
drugstore. Further, it relocated 18 retail drugstores.
At the end of the quarter, the company operated 7,346 locations
including 7,226 retail drugstores, 31 specialty pharmacy stores, 32
apothecary pharmacy stores, 13 specialty mail order pharmacies and
4 mail order pharmacies in 44 states, including the District of
Columbia and Puerto Rico.
Guidance
Based on a solid quarter and incremental start-up costs for the
new business in 2012, CVS has narrowed down its EPS outlook for
fiscal 2011. The company now expects adjusted EPS of $2.75–$2.81
(earlier guidance being $2.72–$2.82). The current Zacks Consensus
Estimate of $2.78 is within this range.
Our Recommendation
We are encouraged by the improved performance of CVS’ Pharmacy
Services segment for the second consecutive quarter, which had
earlier been a drag on the company’s performance. Moreover, the
acquisition of the Medicare Part D business is a good move
companion the company’s part to boost its PBM segment further. We
are also encouraged by CVS’ several recent contract wins over
Medco (MHS) in the recent past which include
Federal Employee Program (FEP) contract in May 2011, as well as the
biggest US public pension fund Calpers.
In addition, we believe the healthcare reform will open up a big
opportunity for the company. We are confident about CVS Caremark’s
longer-term potential based on its retail execution, deployment
potential and the strong 2012 generics cycle. We are currently
Neutral on the stock.
AETNA INC-NEW (AET): Free Stock Analysis Report
CVS CAREMARK CP (CVS): Free Stock Analysis Report
MEDCO HLTH SOL (MHS): Free Stock Analysis Report
UNIVL AMERICAN (UAM): Free Stock Analysis Report
Zacks Investment Research
Aetna (NYSE:AET)
Historical Stock Chart
From Apr 2024 to May 2024
Aetna (NYSE:AET)
Historical Stock Chart
From May 2023 to May 2024